ABL Diagnostics (ABLD) Announces the Submission of a Takeover Bid for Texcell France
Regulatory News:
ABL Diagnostics (Paris:ABLD) (Euronext Paris – Compartment B – ISIN: FR001400AHX6), a company specialized in molecular diagnostic solutions, healthcare software, and clinical sample management, announces that on Tuesday, June 9, 2026, it submitted a bid to acquire the business and assets of TEXCELL, a company specialized in viral safety testing, immunology, and R&D services for biopharmaceutical products, currently subject to judicial reorganization proceedings before the Commercial Court of Évry.
This initiative is part of ABL Diagnostics’ development strategy aimed at assessing external growth opportunities complementary to its current portfolio.
This proposed acquisition, based on Article L. 642-1 of the French Commercial Code, remains subject to the decision of the Commercial Court of Évry. At this stage, there is no certainty as to the outcome of these insolvency proceedings.
